treatment failures occur frequently with reported mortality rates of. 5% to 10%. We present ... this therapeutic option in life-threatening DRESS syndrome resistant.
Severe DRESS Syndrome Managed With Therapeutic Plasma Exchange AUTHORS: Thomas Alexander, MD, MPH,a Edward Iglesia BA,b Yara Park, MD,c Daniel Duncan, MD,c David Peden, MD, MS,a,d Saira Sheikh, MD,a and Maria Ferris, MD, MPH, PhDa Departments of aPediatrics, cPathology and Laboratory Medicine, and dMicrobiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; and bRobert Wood Johnson Medical School, Piscataway Township, New Jersey KEY WORDS adverse drug reaction, plasma exchange, drug hypersensitivity, lamotrigine, bupropion ABBREVIATIONS CMV—cytomegalovirus DRESS—drug reaction with eosinophilia and systemic symptoms EBV—Epstein-Barr virus HHV—human herpes virus IVIg—intravenous immunoglobulin PLEX—plasma exchange TNF—tumor necrosis factor Dr Alexander wrote the description of the case and portions of the discussion; Mr Iglesia wrote portions of the discussion; Dr Ferris developed the treatment plan and reviewed the case report and discussion; Dr Park consulted on the treatment plan and contributed to the discussion; Dr Duncan wrote portions of the discussion; Dr Peden consulted on the treatment plan and reviewed the case report and discussion; and Dr Sheikh contributed to the initial discussion and reviewed the discussion write up.
abstract Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a rare but increasingly described phenomenon of immune activation and organ dysfunction in association with a wide variety of medications. This reaction shows a broad spectrum of clinical presentation and severity, ranging from mild to lethal. Treatment strategies of immune suppression appear be helpful in some cases, but treatment failures occur frequently with reported mortality rates of 5% to 10%. We present a pediatric case of DRESS syndrome associated with either lamotrigine or bupropion, leading to multiorgan involvement and life-threatening complications of respiratory failure and cardiac arrest. After failing to improve with removal of these medications and administration of systemic corticosteroids, our patient showed dramatic, sustained clinical response to therapeutic plasma exchange. To our knowledge, this is the ﬁrst reported case of therapeutic plasma exchange used for life-threatening DRESS syndrome in a pediatric patient. This case suggests needed research for this therapeutic option in life-threatening DRESS syndrome resistant to high-dose steroids. Pediatrics 2013;131:e945–e949
www.pediatrics.org/cgi/doi/10.1542/peds.2012-2117 doi:10.1542/peds.2012-2117 Accepted for publication Nov 5, 2012 Address correspondence to Thomas Alexander, MD, MPH, 3516 Keats Place, Raleigh, NC 27609. E-mail: [email protected]
com PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275). Copyright © 2013 by the American Academy of Pediatrics FINANCIAL DISCLOSURE: The authors have indicated they have no ﬁnancial relationships relevant to this article to disclose. FUNDING: No external funding.
PEDIATRICS Volume 131, Number 3, March 2013
DRESS syndrome is a type of drug hypersensitivity deﬁned by a constellation of ﬁndings associated with hyperinﬂammation related to a medication exposure. The syndrome or a variation has been described in the literature since the 1950s under the names drug-induced pseudolymphoma, anticonvulsant hypersensitivity syndrome, drug-induced delayed multiorgan hypersensitivity syndrome, and druginduced hypersensitivity syndrome.1–5 Kardaun et al describe the following general features of hypersensitivity syndrome/DRESS syndrome1: druginduced immunologic background, later onset than other drug reactions, longer duration than common “drug rashes,” multiorgan involvement, lymphocyte activation, eosinophilia, and frequent virus reactivation. Although it was initially reported in association with anticonvulsant medications,2 it has since been associated with most medication classes.6 Bocquet et al ﬁrst presented the name DRESS during a review of what was previously termed hypersensitivity syndrome.3 As initially deﬁned by Bocquet et al, DRESS diagnostic criteria required cutaneous drug eruption, hematologic abnormalities, and systemic involvement.3 The nomenclature DRESS may cause confusion because eosinophilia is not required to make the diagnosis. The diagnosis is particularly challenging because of delayed symptom onset, the wide spectrum of clinical presentation and organ involvement, and the variety of nomenclature for the syndrome.7,8
CASE DESCRIPTION A 14-year-old African American girl with no signiﬁcant medical history was admitted to an inpatient psychiatric unit for suicidal ideation, diagnosed with bipolar disorder, and treated with lamotrigine and bupropion. Seventeen days after initiation of these 2 medications, she developed a generalized e946
ALEXANDER et al
erythematous skin rash, high-grade fevers, and lymphadenopathy. She presented to an emergency department, where she was prescribed clindamycin for acute lymphadenitis. Two weeks later, she was admitted to the hospital with fever, rash, diffuse tender lymphadenopathy, painful exudative pharyngitis, and glossitis. Laboratory investigation revealed transaminitis, eosinophilia, and atypical lymphocytes, leading to concern for an adverse drug reaction. Lamotrigine and bupropion were stopped, and the patient improved with supportive care. She was discharged, only to return twice with generalized pain, fever, severe painful exudative pharyngitis, and glossitis. Workup was negative for antinuclear antibody; double-stranded DNA; HIV; Epstein-Barr virus (EBV); cytomegalovirus (CMV); hepatitis A, B, and C; streptococcal pharyngitis; urinary tract infection; bacteremia; human herpes virus type 6 titer; and mononucleosis. She was transferred to a tertiary care center for management of acute kidney injury 46 days after the initiation of lamotrigine and bupropion. Around the time of transfer, she had improvement in her skin rash and hepatitis but suffered from volume overload, anemia, pancreatitis, kidney injury, and thyroiditis. A percutaneous ultrasoundassisted renal biopsy revealed severe acute and subacute tubulointerstitial nephritis with granulomatous inﬂammation. Systemic steroids (intravenous methylprednisolone 250 mg daily) were started on day 49, and her renal function began to improve. However, on day 50, she developed respiratory distress, necessitating intensive care. Two days later, on day 52, she was intubated for hypoxic respiratory failure. Much later in the same day, she had a 6-minute cardiac arrest secondary to torsades de pointes. She received 1 dose of epinephrine and 1 episode of cardioversion with subsequent return of spontaneous
circulation. At the time of cardiac arrest, magnesium level was 1.9 mg/dL, and potassium level was 5.0 mmol/L. Her QTc was prolonged to 521 ms hours before the cardiac arrest. Her QT interval was normal on admission to the tertiary care center and normal on follow-up as an outpatient. The etiology of her QT prolongation, torsades de pointes electrical rhythm, and cardiac arrest is not clear but could have been secondary to systemic inﬂammation or myocarditis or possibly medication effect. She did not receive any known QT prolonging medication on the day of the arrest. In light of her rapidly progressive clinical deterioration in the setting of DRESS syndrome and incomplete response to IV corticosteroids, we elected to proceed promptly with plasma exchange (PLEX), although we also considered intravenous immunoglobulin (IVIg), immunomodulators, and the continuation of high-dose steroids. PLEX was performed every other day for a total of 4 procedures. One plasma volume was exchanged with each procedure, and 5% albumin was used as replacement. She tolerated all the procedures well. Within 12 hours of the ﬁrst PLEX session, her course improved dramatically. She ﬁnally became afebrile, her pancreatic enzymes decreased by 50% from 6059 to 3051 U/L. C-reactive protein fell rapidly, and she was extubated without complication 4 days after initiation of PLEX. Her endomyocardial biopsy performed 4 days after initiation of PLEX did not show signs of inﬂammation or eosinophilia. Her liver function, renal function, and eosinophilia continued to trend positively and she was discharged on day 68 with a slow prednisone taper over 2 months in attempt to continue to suppress inﬂammation. In follow-up 3 weeks after discharge, she showed continued clinical and laboratory improvement. At 3 months, she was asymptomatic, with normal laboratory values except for treated hypothyroidism (Figure 1).
DISCUSSION Using the RegiSCAR scoring system proposed by Kardaun et al, our patient had a “deﬁnite” case of DRESS.1 Additionally, our patient met the criteria for the diagnosis of DRESS or “atypical drug-induced hypersensitivity syndrome” under the criteria set forth by Bocquet et al and the Japanese consensus group, respectively.3,9 Despite
meeting diagnostic criteria, our patient’s asynchronous timing of clinical manifestations made the diagnosis difﬁcult. Her skin rash and hepatitis were improving when she ﬁrst showed signs of acute kidney injury. The exact onset of thyroid and pancreatic involvement is unclear. Her pulmonary and cardiac symptoms did not present clinically until her rash had resolved and hepatitis was improving. The exact etiology
of her cardiac arrest remains unclear because her endomyocardial biopsy and cardiac enzyme levels were normal. Notably, our patient had evidence of inﬂammation in 6 organ systems in addition to the hematologic and skin abnormalities. The pathogenesis of DRESS remains incompletely understood. At least 44 drugs have been reported to be associated with DRESS, including, most frequently, aromatic anticonvulsants.6 Lamotrigine is a well-described medication leading to DRESS syndrome.10–12 Bupropion has not been shown to cause DRESS but has been associated with mild serum sickness reactions.13 Clindamycin has not been associated with DRESS and is temporally unlikely to be the culprit medication in our case. Suggested mechanisms for DRESS and other hypersensitivity syndromes include reactive metabolites leading to stimulation of CD4+ and CD8+ T cells through a variety of mechanisms,14–17 and interleukin-5 and tumor necrosis factor (TNF)-a release from CD4+ and CD8+ cells, resulting in activation of eosinophils and inﬂammation.18,19 In DRESS syndrome speciﬁcally, studies have shown an oligoclonal proliferation of activated virus-speciﬁc and nonspeciﬁc T cells resulting from sequential reactivation of the herpes viruses HHV-6, HHV-7, EBV, and CMV,15,20–23 especially in the setting of drug-induced hypogammaglobulinemia permitting viral reactivation.24,25 Parvovirus B19 and mycoplasma can lead to ﬁndings similar to DRESS syndrome.26–28 Our patient had negative EBV, CMV, and HHV-6 titers. We did not assess for HHV-7 reactivation, mycoplasma infection, or parvovirus B19 infection.
FIGURE 1 Timeline of events (symptoms, laboratory markers of organ dysfunction, presentation to medical care, transfer to tertiary care center, and therapeutic interventions). **Exposure to lamotrigine and bupropion.
PEDIATRICS Volume 131, Number 3, March 2013
The management of DRESS calls for early recognition and withdrawal of offending medications. Current treatment is variable, and reports are conﬂicting. It is unclear if other drug reactions have similar enough e947
pathogenesis that therapeutic trials of Stevens-Johnson syndrome or toxic epidermal necrolysis should directly inform treatment of DRESS. Systemic corticosteroids are the current cornerstone of treatment of DRESS.29,30 Options that have been successfully used in the face of clinical deterioration include pulsed methylprednisolone,31 other immunosuppressive agents such as cyclosporine and cyclophosphamide,32–34 and IVIg.35–37 Acute pancreatitis dampened enthusiasm for using pulse corticosteroids in this patient. Although adverse effects may accompany PLEX and IVIg administration, we favored these interventions because of their rapid onset of action. We chose PLEX over IVIg because a recent description of 6 patients with DRESS treated with IVIg suggested that risk outweighed beneﬁts.38 Furthermore, we were concerned about volume overload with IVIg infusion. We were ﬁnally concerned that the cardiac arrest may have been due to myocarditis, and a recent reported case of DRESS with myocarditis responded to PLEX plus rituximab.39
Increased circulating cytokines likely contribute to the pathogenesis of DRESS, and we reasoned that reduction of circulating cytokine levels would result in prompt clinical improvement. PLEX reduces systemic cytokines in other settings of acute systemic inﬂammatory disease. In a study of patients with life-threatening meningococcal infections, PLEX accelerated the decline in TNF-a as well as TNF soluble receptors.40 Similarly, PLEX has lowered circulating concentrations of TNF-a and interleukin-6 in patients with acute liver failure.41 Finally, a prospective trial comparing PLEX to standard of care for patients with sepsis and multiorgan system failure demonstrated a signiﬁcant increase in survival of septic patients receiving PLEX.42 The reported action of PLEX to rapidly remove circulating cytokines in a nonspeciﬁc fashion and improve survival of septic patients was the basis for our decision to use PLEX in our patient.
withdrawal for .2 weeks and 250 mg of methylprednisolone IV for 4 days. She was intubated, had a 6-minute cardiac arrest, and remained persistently febrile with continued signs of multiorgan dysfunction. We therefore proceeded with PLEX based on the above thought process and a previous report of using PLEX in the setting of DRESS and myocarditis.39 Our patient showed marked improvement of systemic inﬂammation and clinical condition coincident with our use of PLEX.
In summary, our patient showed unquestionable clinical deterioration despite lamotrigine and bupropion
We feel that this outcome supports the hypothesis that PLEX can effectively and rapidly reduce morbidity and mortality in patients with inﬂammation like that encountered with DRESS that are resistant to corticosteroids. Furthermore, PLEX has fewer toxicities than are encountered with many other immunosuppressives. Given the paucity of evidence regarding treatment of acute systemic drug reactions, we advocate for a multicenter prospective randomized study of the efﬁcacy of PLEX in DRESS and similar diseases.
been sufﬁciently established on the basis of typical clinical features and viral reactivations. Br J Dermatol. 2007;156(5):1083– 1084 Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: a literature review. Am J Med. 2011;124(7):588–597 Peyrière H, Dereure O, Breton H, et al; Network of the French Pharmacovigilance Centers. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2006;155(2): 422–428 Kano Y, Shiohara T. The variable clinical picture of drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug. Immunol Allergy Clin North Am. 2009;29(3):481–501 Tohyama M, Hashimoto K. New aspects of drug-induced hypersensitivity syndrome. J Dermatol. 2011;38(3):222–228
10. Mylonakis E, Vittorio CC, Hollik DA, Rounds S. Lamotrigine overdose presenting as anticonvulsant hypersensitivity syndrome. Ann Pharmacother. 1999;33 (5):557–559 11. Amante MF, Filippini AV, Cejas N, Lendoire J, Imventarza O, Parisi C. Dress syndrome and fulminant hepatic failure induced by lamotrigine. Ann Hepatol. 2009;8(1):75–77 12. Roquin G, Peres M, Lerolle N, et al. First report of lamotrigine-induced drug rash with eosinophilia and systemic symptoms syndrome with pancreatitis. Ann Pharmacother. 2010;44(12):1998–2000 13. Beyens MN, Guy C, Mounier G, Laporte S, Ollagnier M. Serious adverse reactions of bupropion for smoking cessation: analysis of the French Pharmacovigilance Database from 2001 to 2004. Drug Saf. 2008;31(11): 1017–1026 14. Shear NH, Spielberg SP, Grant DM, Tang BK, Kalow W. Differences in metabolism of sulfonamides predisposing to idiosyncratic
REFERENCES 1. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2007;156(3): 609–611 2. Saltzstein SL, Ackerman LV. Lymphadenopathy induced by anticonvulsant drugs and mimicking clinically pathologically malignant lymphomas. Cancer. 1959;12(1):164– 182 3. Bocquet H, Bagot M, Roujeau JC. Druginduced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS). Semin Cutan Med Surg. 1996;15(4):250–257 4. Sontheimer RD, Houpt KR. DIDMOHS: a proposed consensus nomenclature for the druginduced delayed multiorgan hypersensitivity syndrome. Arch Dermatol. 1998;134(7):874– 876 5. Shiohara T, Iijima M, Ikezawa Z, Hashimoto K. The diagnosis of a DRESS syndrome has
ALEXANDER et al
toxicity. Ann Intern Med. 1986;105(2):179– 184 Picard D, Janela B, Descamps V, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med. 2010;2(46): 46ra62 Pichler WJ, Naisbitt DJ, Park BK. Immune pathomechanism of drug hypersensitivity reactions. J Allergy Clin Immunol. 2011;127 (suppl 3):S74–S81 Williams DP, Kitteringham NR, Naisbitt DJ, Pirmohamed M, Smith DA, Park BK. Are chemically reactive metabolites responsible for adverse reactions to drugs? Curr Drug Metab. 2002;3(4):351–366 Boet S, Noblet C, Haas-Hubscher C, Picard D, Musette P, Dureuil B. Severe vancomycininduced drug rash with eosinophilia and systemic symptoms syndrome imitating septic shock. Eur J Anaesthesiol. 2009;26 (9):791–793 Choquet-Kastylevsky G, Intrator L, Chenal C, Bocquet H, Revuz J, Roujeau JC. Increased levels of interleukin 5 are associated with the generation of eosinophilia in druginduced hypersensitivity syndrome. Br J Dermatol. 1998;139(6):1026–1032 Descamps V, Valance A, Edlinger C, et al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol. 2001;137(3):301–304 Kano Y, Hiraharas K, Sakuma K, Shiohara T. Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graftversus-host disease. Br J Dermatol. 2006; 155(2):301–306 Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol Int. 2006;55(1):1–8 Pritchett JC, Nanau RM, Neuman MG. The link between hypersensitivity syndrome reaction development and human herpes virus-6 reactivation. Int J Hepatol. 2012; 2012:723062 Aihara Y, Ito SI, Kobayashi Y, Yamakawa Y, Aihara M, Yokota S. Carbamazepine-induced
PEDIATRICS Volume 131, Number 3, March 2013
hypersensitivity syndrome associated with transient hypogammaglobulinaemia and reactivation of human herpesvirus 6 infection demonstrated by real-time quantitative polymerase chain reaction. Br J Dermatol. 2003;149(1):165–169 Kano Y, Shiohara T. Sequential reactivation of herpesvirus in drug-induced hypersensitivity syndrome. Acta Derm Venereol. 2004;84(6):484–485 Kosseian-Bal I, Bocquet H, Beneton N, et al. Hypersensitivity syndrome during Mycoplasma pneumoniae infection [in French]. Ann Dermatol Venereol. 1998;125(5):328– 330 Barash J, Dushnitzky D, Sthoeger D, Bardenstein R, Barak Y. Human parvovirus B19 infection in children: uncommon clinical presentations. Isr Med Assoc J. 2002; 4(10):763–765 Regnier S, Descamps V, Boui M, et al. Parvovirus B19 infection mimicking druginduced hypersensitivity syndrome [in French]. Ann Dermatol Venereol. 2000;127 (5):505–506 Eshki M, Allanore L, Musette P, et al. Twelveyear analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. Arch Dermatol. 2009;145(1): 67–72 Uhara H, Saiki M, Kawachi S, Ashida A, Oguchi S, Okuyama R. Clinical course of drug-induced hypersensitivity syndrome treated without systemic corticosteroids [published online ahead of print April 28, 2012]. J Eur Acad Dermatol Venereol. PubMeddoi:10.1111/j.1468-3083.2012.04547.x Natkunarajah J, Goolamali S, Craythorne E, et al. Ten cases of drug reaction with eosinophilia and systemic symptoms (DRESS) treated with pulsed intravenous methylprednisolone. Eur J Dermatol. 2011;21(3): 385–391 Harman KE, Morris SD, Higgins EM. Persistent anticonvulsant hypersensitivity syndrome responding to ciclosporin. Clin Exp Dermatol. 2003;28(4):364–365 Zuliani E, Zwahlen H, Gilliet F, Marone C. Vancomycin-induced hypersensitivity reaction with acute renal failure: resolution
following cyclosporine treatment. Clin Nephrol. 2005;64(2):155–158 Laban E, Hainaut-Wierzbicka E, Pourreau F, et al. Cyclophosphamide therapy for corticoresistant drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in a patient with severe kidney and eye involvement and Epstein-Barr virus reactivation. Am J Kidney Dis. 2010;55(3):e11– e14 Fields KS, Petersen MJ, Chiao E, TristaniFirouzi P. Case reports: treatment of nevirapine-associated dress syndrome with intravenous immune globulin (IVIG). J Drugs Dermatol. 2005;4(4):510–513 Santos RP, Ramilo O, Barton T. Nevirapineassociated rash with eosinophilia and systemic symptoms in a child with human immunodeﬁciency virus infection. Pediatr Infect Dis J. 2007;26(11):1053–1056 Kito Y, Ito T, Tokura Y, Hashizume H. Highdose intravenous immunoglobulin monotherapy for drug-induced hypersensitivity syndrome. Acta Derm Venereol. 2012;92(1): 100–101 Joly P, Janela B, Tetart F, et al. Poor beneﬁt/ risk balance of intravenous immunoglobulins in DRESS. Arch Dermatol. 2012;148(4): 543–544 Shaughnessy KK, Bouchard SM, Mohr MR, Herre JM, Salkey KS. Minocycline-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome with persistent myocarditis. J Am Acad Dermatol. 2010;62(2):315–318 van Deuren M, Frieling JT, van der VenJongekrijg J, et al. Plasma patterns of tumor necrosis factor-alpha (TNF) and TNF soluble receptors during acute meningococcal infections and the effect of plasma exchange. Clin Infect Dis. 1998;26(4):918– 923 Iwai H, Nagaki M, Naito T, et al. Removal of endotoxin and cytokines by plasma exchange in patients with acute hepatic failure. Crit Care Med. 1998;26(5):873–876 Busund R, Koukline V, Utrobin U, Nedashkovsky E. Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Intensive Care Med. 2002; 28(10):1434–1439